LONDON (AFX) - Biopharmaceutical company SR Pharma PLC said it will proceed with a full, 28-day toxicological evaluation of its RNAi product candidate Atu027 before starting clinical testing later this year.
LONDON (AFX) - Biopharmaceutical company SR Pharma PLC said it will proceed with a full, 28-day toxicological evaluation of its RNAi product candidate Atu027 before starting clinical testing later this year.